

1. **The impact of age on the diagnosis and therapy of myelodysplastic syndromes: results from a retrospective multicenter analysis in Germany.** Gattermann N, Kündgen A, Kellermann L, Zeffel M, Paessens B, Germing U, Eur J Haematol 2013 Dec; 91(6)
2. **Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients.** Platzbecker U, Al-Ali HK, Gattermann N, Haase D, Janzen V, Krauter J, Götze K, Schlenk R, Nolte F, Letsch A, Ottmann OG, Kündgen A, Lübbert M, Germing U, Wermke M, Reinhard H, Weiss C, Lieder K, Ehninger G, Leismann O, Giagounidis A. Leukemia. 2013 Nov 4. doi: 10.1038
3. **Mesenchymal stromal cells from patients with myelodysplastic syndrome display distinct functional alterations that are modulated by lenalidomide.** Ferrer RA, Wobus M, List C, Wehner R, Schönfeldt C, Brocard B, Mohr B, Rauner M, Schmitz M, Stiehler M, Ehninger G, Hofbauer LC, Bornhäuser M, Platzbecker U. Haematologica. 2013 Nov;98(11):1677-85
4. **Proposed score for survival of patients with myelodysplastic syndromes.** Sperr WR, Kundi M, Wimazal F, Nösslinger T, Schönmetzler-Makrai A, Stauder R, Krieger O, Neukirchen J, Germing U, Pfeilstöcker M, Valent P. Eur J Clin Invest. 2013 Nov; 43(11):1120-8. Doi
5. **Comparison of allogeneic stem cell transplantation and non-transplant approaches in elderly patients with advanced myelodysplastic syndrome: optimal statistical approaches and a critical appraisal of clinical results using non-randomized data.** Brand R, Putter H, van Biezen A, Niederwieser D, Martino R, Mufti G, Onida F, Symeonidis A, Schmid C, Garderet L, Robin M, van Gelder M, Finke J, Bornhäuser M, Kobbe G, Germing U, de Witte T, Kröger N. PLoS One. 2013 Oct 7;8(10):e7
6. **SETBP1 mutation analysis in 944 patients with MDS and AML.** Thol F, Suchanek KJ, Koenecke C, Stadler M, Platzbecker U, Thiede C, Schroeder T, Kobbe G, Kade S, Löffeld P, Banihosseini S, Bug G, Ottmann O, Hofmann WK, Krauter J, Kröger N, Ganser A, Heuser M. Leukemia. 2013 Oct;27(10):2072-5. Doi
7. **Monosomal karyotype in MDS: explaining the poor prognosis?** Schanz J, Tüchler H, Solé F, Mallo M, Luño E, Cervera J, Grau J, Hildebrandt B, Slovak ML, Ohyashiki K, Steidl C, Fonatsch C, Pfeilstöcker M, Nösslinger T, Valent P, Giagounidis A, Aul C, Lübbert M, Stauder R, Krieger O, Le Beau MM, Bennett JM, Greenberg P, Germing U, Haase D. Leukemia. 2013 Oct;27(10):1988-95. doi:
8. **Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation.** Schroeder T, Fröbel J, Cadeddu RP, Czibere A, Dienst A, Platzbecker U, Bug G, Uharek L, Fenk R, Germing U, Kröger N, Haas R, Kobbe G. Leukemia. 2013 Sep;27(9):1910-3. doi: 10.1038
9. **Combination of azacitidine and lenalidomide in myelodysplastic syndromes or acute myeloid leukemia-a wise liaison?** Platzbecker U, Germing U. Leukemia. 2013 Sep;27(9):1813-9. Review.

10. **Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate -1 MDS?** Santini V, Schemenau J, Levis A, Balleari E, Sapena R, Adès L, Guerci A, Beyne-Rauzy O, Gourin MP, Cheze S, Stamatoullas A, Sanna A, Gioia D, Cametti G, Ferrero D, Raffoux E, Rose C, Poloni A, Prebet T, Legros L, Natarajan-Amé S, Fenaux P, Germing U, Dreyfus F, Park S. *Blood*. 2013 Sep 26;122(13):2286-8.
11. **Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis.** Broséus J, Alpermann T, Wulfert M, Florensa Brichs L, Jeromin S, Lippert E, Rozman M, Lifermann F, Grossmann V, Haferlach T, Germing U, Luño E, Girodon F, Schnittger S; MPN and MPNr-EuroNet (COST Action BM0902). *Leukemia*. 2013 Sep;27(9):1826-31
12. **Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: first results from a prospective multicenter German diagnostic study.** Braulke F, Jung K, Schanz J, Götze K, Müller-Thomas C, Platzbecker U, Germing U, Brümmendorf TH, Bug G, Ottmann O, Giagounidis AA, Stadler M, Hofmann WK, Schafhausen P, Lübbert M, Schlenk RF, Blau IW, Ganster C, Pfeiffer S, Shirneshan K, Metz M, Detken S, Seraphin J, Jentsch-Ullrich K, Böhme A, Schmidt B, Trümper L, Haase D. *Leuk Res*. 2013 Aug;37(8):900-6.
13. **Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study.** Platzbecker U, Braulke F, Kündgen A, Götze K, Bug G, Schönfeldt C, Shirneshan K, Röllig C, Bornhäuser M, Naumann R, Neesen J, Giagounidis A, Hofmann WK, Ehninger G, Germing U, Haase D, Wermke M. *Leukemia*. 2013 Jun; 27(6):1403-7. Doi
14. **Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation.** Schroeder T, Czibere A, Platzbecker U, Bug G, Uharek L, Luft T, Giagounidis A, Zohren F, Bruns I, Wolschke C, Rieger K, Fenk R, Germing U, Haas R, Kröger N, Kobbe G. *Leukemia*. 2013 Jun;27(6):1229-35
15. **Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis.** Kuendgen A, Lauseker M, List AF, Fenaux P, Giagounidis AA, Brandenburg NA, Backstrom J, Glasmacher A, Hasford J, Germing U; International Working Group on MDS with del(5q). *Leukemia*. 2013 Apr;27(5):1072-9
16. **Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group.** van de Loosdrecht AA, Ireland R, Kern W, Della Porta MG, Alhan C, Balleisen JS, Bettelheim P, Bowen DT, Burbury K, Eidschink L, Cazzola M, Chu SS, Cullen M, Cutler JA, Dräger AM, Feuillard J, Fenaux P, Font P, Germing U, Haase D, Hellström-Lindberg E, Johansson U, Kordestani S, Loken MR, Malcovati L, te Marvelde JG, Matarraz S, Milne T, Moshaver B, Mufti GJ, Nikolova V, Ogata K, Oelschlaegel U, Orfao A, Ossenkoppele GJ, Porwit A, Platzbecker U, Preijers F, Psarra K, Richards SJ, Subirá D, Seymour JF, Tindell V, Vallespi T, Valent P, van der Velden VH, Wells DA, de Witte TM, Zetti F, Béné MC, Westers TM. *Leuk Lymphoma*. 2013 Mar;54(3):472-5.
17. **Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome.** Deschler B, Ihorst G, Platzbecker U, Germing U, März E, de

Figuerido M, Fritzsche K, Haas P, Salih HR, Giagounidis A, Selleslag D, Labar B, de Witte T, Wijermans P, Lübbert M. *Haematologica*. 2013 Feb;98(2):208-16

18. **Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.** Nolte F, Höchsmann B, Giagounidis A, Lübbert M, Platzbecker U, Haase D, Lück A, Gattermann N, Taupitz M, Baier M, Leismann O, Junkes A, Schumann C, Hofmann WK, Schrezenmeier H. *Ann Hematol*. 2013 Jan; 92(2):191-8.